The Next Frontier For GLP-1 Medications: Potential Therapy For Inflammation
GLP-1 medications, known for their weight-loss benefits, may also help reduce chronic inflammation. A recent study indicates that semaglutide can alleviate osteoarthritis-related inflammation and tissue damage, independent of weight loss. Efforts are underway to improve access to these medications, particularly for Medicare beneficiaries.
- ▪GLP-1 medications like Ozempic and Wegovy have shown potential in reducing chronic inflammation.
- ▪A study published in Cell Metabolism found that semaglutide may help alleviate osteoarthritis-related inflammation and tissue damage.
- ▪The Centers for Medicare and Medicaid Services has launched a Medicare GLP-1 Bridge program to increase access to these medications.
Opening excerpt (first ~120 words) tap to expand
InnovationHealthcareThe Next Frontier For GLP-1 Medications: Potential Therapy For InflammationByDr. Sai Balasubramanian, M.D., J.D.,Contributor.Forbes contributors publish independent expert analyses and insights. Sai writes about healthcare, innovation and technology.Follow AuthorMay 25, 2026, 08:16pm EDT--:-- / --:--This voice experience is generated by AI. Learn more.This voice experience is generated by AI. Learn more.According to a new study, GLP-1s may be potentially effective in reducing chronic inflammation.gettyGLP-1 medications such as Ozempic, Wegovy and Mounjaro have dominated headlines in recent years for their significant potential in helping individuals with weight-loss.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Forbes — Business.
Discussion
0 commentsMore from Forbes — Business
